We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

93 hedge funds and large institutions have $888M invested in Adaptimmune Therapeutics in 2018 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 18 increasing their positions, 36 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

303% more call options, than puts

Call options by funds: $10.3M | Put options by funds: $2.56M

64% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 11

34% more capital invested

Capital invested by funds: $663M → $888M (+$225M)

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

8% more funds holding

Funds holding: 86 → 93 (+7)

1.68% more ownership

Funds ownership: 9.88% → 11.57% (+1.7%)

50% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 36

Holders
93
Holders Change
+7
Holders Change %
+8.14%
% of All Funds
2.13%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.14%
New
18
Increased
18
Reduced
36
Closed
11
Calls
$10.3M
Puts
$2.56M
Net Calls
+$7.74M
Net Calls Change
+$6.31M

Top Buyers

Rank Fund Capital Flow
1
MCMC
Matrix Capital Management Company
New Hampshire
+$65.8M
2
NMC
NEA Management Company
Maryland
+$26.2M
3
Millennium Management
Millennium Management
New York
+$13.9M
4
SLG
Stanley-Laman Group
Pennsylvania
+$5.93M
5
FCM
Frontier Capital Management
Massachusetts
+$5.7M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$12.4M
2
TCM
Tekla Capital Management
Massachusetts
-$5.28M
3
OIM
Oracle Investment Management
Connecticut
-$5.2M
4
Capital World Investors
Capital World Investors
California
-$4.13M
5
Renaissance Technologies
Renaissance Technologies
New York
-$2.81M
Name Holding Trade Value Shares
Change 		Change in
Stake
A
26
Abingworth
United Kingdom
$3.39M – – –
Citadel Advisors
27
Citadel Advisors
Florida
$3.31M +$1.37M +131,009 +116%
RG
28
Rathbones Group
United Kingdom
$3.03M -$210K -20,000 -8%
VIA
29
Vident Investment Advisory
Georgia
$2.61M -$141K -13,450 -7%
GAMA
30
Graticule Asia Macro Advisors
New York
$2.51M +$1.1M +105,000 +131%
EIM
31
Essex Investment Management
Massachusetts
$2.27M -$4.52K -431 -0.3%
JP Morgan Chase
32
JP Morgan Chase
New York
$2.01M -$665K -63,465 -30%
Ameriprise
33
Ameriprise
Minnesota
$1.68M -$1.29M -123,146 -50%
Creative Planning
34
Creative Planning
Kansas
$1.64M +$189K +18,000 +17%
UBS Group
35
UBS Group
Switzerland
$1.6M +$1.11M +106,170 +911%
Stifel Financial
36
Stifel Financial
Missouri
$1.22M +$952K +90,856 New
SI
37
Sofinnova Investments
California
$1.22M +$943K +89,919 New
NC
38
Nexthera Capital
New York
$1M +$777K +74,132 New
WMSA
39
Weiss Multi-Strategy Advisers
New York
$949K -$105K -10,000 -13%
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
$878K +$679K +64,763 New
NIMI
41
Natixis Investment Managers International
France
$859K -$442K -42,119 -40%
BG
42
Bellevue Group
Switzerland
$794K -$14.7K -1,400 -2%
PCM
43
Prelude Capital Management
New York
$715K -$1.46K -139 -0.3%
Geode Capital Management
44
Geode Capital Management
Massachusetts
$537K -$15.5K -1,482 -4%
VEA
45
Virtus ETF Advisers
New York
$510K -$290K -27,618 -42%
California Public Employees Retirement System
46
California Public Employees Retirement System
California
$497K -$11.8K -1,128 -3%
State Street
47
State Street
Massachusetts
$492K – – –
Parallax Volatility Advisers
48
Parallax Volatility Advisers
California
$412K +$315K +30,065 +10,022%
ProShare Advisors
49
ProShare Advisors
Maryland
$367K -$5.41K -516 -2%
Goldman Sachs
50
Goldman Sachs
New York
$357K -$158K -15,051 -36%
1
2
3 4 5

ADAP Hedge Fund Activity: Q3 2018 in Review

93 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q3 2018, worth a combined $888M — up 34% from $663M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new ADAP positions and 11 closed out — a net gain of 7 holders — while 18 added to existing stakes and 36 trimmed.

The largest buyer was Matrix Capital Management Company, adding an estimated $65.8M. The largest seller was Fidelity Investments, cutting an estimated $12.4M.

  • 93 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q3 2018, up from 86 in Q2 2018.
  • Funds reported $888M of Adaptimmune Therapeutics stock for Q3 2018, up 34% quarter-over-quarter.
  • 18 funds opened new Adaptimmune Therapeutics positions in Q3 2018 and 11 closed out, a net change of +7 holders.
  • The largest Adaptimmune Therapeutics buyer in Q3 2018 was Matrix Capital Management Company, an estimated $65.8M added.
  • The largest Adaptimmune Therapeutics seller in Q3 2018 was Fidelity Investments, an estimated $12.4M sold.

Based on aggregated 13F filings for Q3 2018.